|
1
|
Lithium-induced increase in human brain grey matter.
|
Lancet
|
2000
|
2.31
|
|
2
|
Enhancement of hippocampal neurogenesis by lithium.
|
J Neurochem
|
2000
|
2.28
|
|
3
|
The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3.
|
J Neurochem
|
1999
|
2.20
|
|
4
|
The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS.
|
J Neurochem
|
1999
|
2.04
|
|
5
|
Protein kinase C overactivity impairs prefrontal cortical regulation of working memory.
|
Science
|
2004
|
1.83
|
|
6
|
The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth.
|
J Biol Chem
|
2001
|
1.73
|
|
7
|
Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2's neurotrophic effects?
|
Biol Psychiatry
|
2000
|
1.55
|
|
8
|
Environmental enrichment requires adult neurogenesis to facilitate the recovery from psychosocial stress.
|
Mol Psychiatry
|
2010
|
1.47
|
|
9
|
Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers.
|
Mol Psychiatry
|
2004
|
1.39
|
|
10
|
Evidence for the involvement of the kainate receptor subunit GluR6 (GRIK2) in mediating behavioral displays related to behavioral symptoms of mania.
|
Mol Psychiatry
|
2008
|
1.36
|
|
11
|
The extracellular signal-regulated kinase pathway contributes to the control of behavioral excitement.
|
Mol Psychiatry
|
2008
|
1.19
|
|
12
|
A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania.
|
Arch Gen Psychiatry
|
2000
|
1.06
|
|
13
|
Temporal dissociation between lithium-induced changes in frontal lobe myo-inositol and clinical response in manic-depressive illness.
|
Am J Psychiatry
|
1999
|
1.05
|
|
14
|
Chronic sodium valproate selectively decreases protein kinase C alpha and epsilon in vitro.
|
J Neurochem
|
1994
|
0.94
|
|
15
|
Rapid antidepressant effects: moving right along.
|
Mol Psychiatry
|
2013
|
0.93
|
|
16
|
Lithium regulates PKC-mediated intracellular cross-talk and gene expression in the CNS in vivo.
|
Bipolar Disord
|
2000
|
0.92
|
|
17
|
Translational research in bipolar disorder: emerging insights from genetically based models.
|
Mol Psychiatry
|
2010
|
0.91
|
|
18
|
G proteins and beta ARK: a new twist for the coiled coil.
|
Trends Biochem Sci
|
1993
|
0.89
|
|
19
|
Regulation of signal transduction pathways and gene expression by mood stabilizers and antidepressants.
|
Psychosom Med
|
1999
|
0.89
|
|
20
|
Lithium activates the c-Jun NH2-terminal kinases in vitro and in the CNS in vivo.
|
J Neurochem
|
1999
|
0.86
|
|
21
|
Valproate robustly enhances AP-1 mediated gene expression.
|
Brain Res Mol Brain Res
|
1999
|
0.86
|
|
22
|
Possible involvement of the ERK signaling cascade in bipolar disorder: behavioral leads from the study of mutant mice.
|
Drug News Perspect
|
2003
|
0.85
|
|
23
|
Signal-transducing G proteins and antidepressant drugs: evidence for modulation of alpha subunit gene expression in rat brain.
|
Biol Psychiatry
|
1992
|
0.85
|
|
24
|
High levels of Gs alpha in platelets of euthymic patients with bipolar affective disorder.
|
Am J Psychiatry
|
1997
|
0.84
|
|
25
|
Lithium increases tyrosine hydroxylase levels both in vivo and in vitro.
|
J Neurochem
|
1998
|
0.84
|
|
26
|
Molecular mechanisms underlying mood stabilization in manic-depressive illness: the phenotype challenge.
|
Am J Psychiatry
|
1999
|
0.84
|
|
27
|
Catecholamines in depression: an update.
|
Clin Chem
|
1994
|
0.84
|
|
28
|
Attenuation of cyclic AMP production by carbamazepine.
|
J Neurochem
|
1996
|
0.84
|
|
29
|
Emerging experimental therapeutics for bipolar disorder: clues from the molecular pathophysiology.
|
Mol Psychiatry
|
2004
|
0.84
|
|
30
|
Neurobiology of lithium: an update.
|
J Clin Psychiatry
|
1998
|
0.82
|
|
31
|
The effects of lithium on ex vivo cytokine production.
|
Biol Psychiatry
|
2001
|
0.81
|
|
32
|
Increase in AP-1 transcription factor DNA binding activity by valproic acid.
|
Neuropsychopharmacology
|
1997
|
0.81
|
|
33
|
Comparative tolerability profiles of the newer versus older antidepressants.
|
Drug Saf
|
1994
|
0.80
|
|
34
|
Lithium stimulates gene expression through the AP-1 transcription factor pathway.
|
Brain Res Mol Brain Res
|
1998
|
0.80
|
|
35
|
Targeting the BH3-interacting domain death agonist to develop mechanistically unique antidepressants.
|
Mol Psychiatry
|
2011
|
0.79
|
|
36
|
The mechanisms of action of lithium. II. Effects on adenylate cyclase activity and beta-adrenergic receptor binding in normal subjects.
|
Arch Gen Psychiatry
|
1991
|
0.79
|
|
37
|
Assessment of bromocriptine intervention for the treatment of frontal lobe syndrome: a case study.
|
J Neuropsychiatry Clin Neurosci
|
1992
|
0.78
|
|
38
|
No abnormality in the gene for the G protein stimulatory alpha subunit in patients with bipolar disorder.
|
Arch Gen Psychiatry
|
1997
|
0.78
|
|
39
|
Lithium treatment in ovo: effects on embryonic heart rate, natural death of ciliary ganglion neurons, and brain expression of a highly conserved chicken homolog of human MTG8/ETO.
|
Brain Res Dev Brain Res
|
2000
|
0.78
|
|
40
|
Concurrent measures of protein kinase C and phosphoinositides in lithium-treated bipolar patients and healthy individuals: a preliminary study.
|
Psychiatry Res
|
2000
|
0.78
|
|
41
|
Effects of valproic acid on beta-adrenergic receptors, G-proteins, and adenylyl cyclase in rat C6 glioma cells.
|
Neuropsychopharmacology
|
1996
|
0.77
|
|
42
|
Chronic Li+ attenuates agonist- and phorbol ester-mediated Na+/H+ antiporter activity in HL-60 cells.
|
Eur J Pharmacol
|
1990
|
0.77
|
|
43
|
Down-regulation of PKC alpha by lithium in vitro.
|
Psychopharmacol Bull
|
1995
|
0.77
|
|
44
|
Lithium administration modulates platelet Gi in humans.
|
Life Sci
|
1992
|
0.76
|
|
45
|
Alterations in cyclic AMP generation and G protein subunits following transient ischemia in gerbil hippocampus.
|
J Cereb Blood Flow Metab
|
1995
|
0.76
|
|
46
|
ECT and delirium in Parkinson's disease.
|
Am J Psychiatry
|
1992
|
0.75
|
|
47
|
Bupropion, ECT, and dopaminergic overdrive.
|
Am J Psychiatry
|
1991
|
0.75
|
|
48
|
G-protein level quantification in platelets and leukocytes from patients with panic disorder.
|
Neuropsychopharmacology
|
1996
|
0.75
|
|
49
|
Commentary on the management of treatment-resistant affective disorder: clinical perspectives.
|
J Psychopharmacol
|
1992
|
0.75
|
|
50
|
In vivo evidence that nonneuronal beta-adrenoceptors as well as dopamine receptors contribute to cyclic AMP efflux in rat striatum.
|
J Neurochem
|
1994
|
0.75
|
|
51
|
Combined measures of noradrenergic output and receptor responsivity in depression.
|
Clin Neuropharmacol
|
1992
|
0.75
|
|
52
|
Pharmacologic profile of natural products used to treat psychotic illnesses.
|
Psychopharmacol Bull
|
1995
|
0.75
|
|
53
|
Effect of the 5-HT2 antagonist ketanserin on the ECT-induced prolactin release.
|
Biol Psychiatry
|
1989
|
0.75
|
|
54
|
Monoaminergic actions of ECT.
|
Clin Neuropharmacol
|
1992
|
0.75
|
|
55
|
Bromocriptine in neuroleptic resistance.
|
Biol Psychiatry
|
1987
|
0.75
|
|
56
|
Platelet α2-adrenoreceptors in depression: a critical examination.
|
J Psychopharmacol
|
1993
|
0.75
|
|
57
|
Antidepressants, metabolites, and apparent drug resistance.
|
Clin Neuropharmacol
|
1990
|
0.75
|
|
58
|
Are monoamine metabolites in cerebrospinal fluid worth measuring?
|
Arch Gen Psychiatry
|
1993
|
0.75
|